SCHEMBL4818210

SCHEMBL4818210

OC1CCN(c2c(-c3c(F)cccc3F)c(Cl)nc3ncnn23)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.41
NPSR1 Q6W5P4 2/20 0.41
GLA P06280 1/20 0.41
PDE2A O00408 5/20 0.38
ALDH1A1 P00352 5/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
PIM1 P11309 2/20 0.36
PIM3 Q86V86 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
TYK2 P29597 1/20 0.35
MAPT P10636 5/20 0.35
LMNA P02545 4/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
HTT P42858 2/20 0.35
KDM4E B2RXH2 1/20 0.34
USP2 O75604 1/20 0.34
TP53 P04637 1/20 0.34
HPGD P15428 1/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4821049 0.90 TSHR (0.42) TSHRNPSR1GLAPDE2AALDH1A1
SCHEMBL4820371 0.89 TSHR (0.48) TSHRNPSR1GLAPDE2AALDH1A1
SCHEMBL7821613 0.89 PDE2A (0.38) TSHRNPSR1GLAPDE2AALDH1A1
SCHEMBL4817651 0.89 TSHR (0.41) TSHRNPSR1GLAPDE2AALDH1A1
SCHEMBL4821987 0.86 TSHR (0.40) TSHRNPSR1GLAPDE2AALDH1A1
SCHEMBL8916786 0.86 TSHR (0.40) TSHRNPSR1GLAPDE2AALDH1A1
SCHEMBL8916215 0.86 TSHR (0.46) TSHRNPSR1GLAPDE2AALDH1A1
SCHEMBL4817364 0.84 TSHR (0.38) TSHRNPSR1GLAPDE2AALDH1A1
SCHEMBL4810572 0.84 PDE2A (0.43) TSHRNPSR1GLAPDE2AALDH1A1
SCHEMBL344327 0.84 TSHR (0.46) TSHRNPSR1GLAPDE2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1307200-A2 SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS Wyeth (US) 2003-05-07 EP claimed
US-20020068744-A1 Substituted-triazolopyrimidines as anticancer agents AMERICAN HOME PRODUCTS CORPORATION 2002-06-06 US claimed
WO-2002002563-A2 SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS WYETH (US) 2002-01-10 WO claimed
US-7329663-B2 Substituted-triazolopyrimidines as anticancer agents WYETH (US) 2008-02-12 US disclosed
US-20020068744-A1 Substituted-triazolopyrimidines as anticancer agents AMERICAN HOME PRODUCTS CORPORATION 2002-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068744-A1 Substituted-triazolopyrimidines as anticancer agents TUBB3, TUBA1C, TUBB1 TSHR 2567/4885NPSR1 4247/4885GLA 3009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.